Section of Endocrinology and Investigative Medicine, Imperial College London, London, UK.
Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK.
J Neuroendocrinol. 2022 Oct;34(10):e13201. doi: 10.1111/jne.13201. Epub 2022 Oct 19.
The reproductive neuropeptide kisspeptin has emerged as the master regulator of mammalian reproduction due to its key roles in the initiation of puberty and the control of fertility. Alongside the tachykinin neurokinin B and the endogenous opioid dynorphin, these peptides are central to the hormonal control of reproduction. Building on the expanding body of experimental animal models, interest has flourished with human studies revealing that kisspeptin administration stimulates physiological reproductive hormone secretion in both healthy men and women, as well as patients with common reproductive disorders. In addition, emerging therapeutic roles based on neurokinin B for the management of menopausal flushing, endometriosis and uterine fibroids are increasingly recognised. In this review, we focus on kisspeptin and neurokinin B and their potential application as novel clinical strategies for the management of reproductive disorders.
生殖神经肽 kisspeptin 因其在青春期启动和生育力控制中的关键作用，已成为哺乳动物生殖的主要调节剂。这些肽与速激肽神经激肽 B 和内源性阿片 dynorphin 一起，是激素控制生殖的核心。基于越来越多的实验动物模型，人们对人类研究产生了浓厚的兴趣，这些研究表明， kisspeptin 的给药可刺激健康男性和女性以及常见生殖障碍患者的生理生殖激素分泌。此外，基于神经激肽 B 的新兴治疗作用越来越多地被认为可用于治疗更年期潮红、子宫内膜异位症和子宫肌瘤。在这篇综述中，我们重点介绍 kisspeptin 和神经激肽 B 及其作为治疗生殖障碍的新型临床策略的潜在应用。
